Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation

M. Yanada, S. Kurosawa, T. Yamaguchi, N. Uchida, S. Miyawaki, H. Kanamori, K. Usuki, T. Kobayashi, M. Watanabe, K. Nagafuji, S. Yano, Y. Nawa, J. Tomiyama, H. Tashiro, Y. Nakamura, S. Fujisawa, F. Kimura, N. Emi, I. Miura, T. Fukuda

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Although allogeneic hematopoietic cell transplantation (HCT) from a related donor is effective therapy for younger patients with AML, it remains unknown how the availability of a related donor affects the outcome when unrelated HCT is a treatment option for patients without a related donor. To address this issue, we retrospectively analyzed 605 cytogenetically non-favorable AML patients younger than 50 years for whom a related donor search was performed during first CR (CR1). The 4-year OS was 62% in 253 patients with a related donor and 59% in 352 patients without a related donor (P=0.534). Allogeneic HCT was performed during CR1 in 62% and 41% of patients with and without a related donor, respectively. Among patients transplanted in CR1, the cumulative incidence of non-relapse mortality was significantly higher in patients without a related donor (P=0.022), but there was no difference in post-transplant OS between the groups (P=0.262). These findings show the usefulness of unrelated HCT in younger patients with cytogenetically non-favorable AML who do not have a related donor. The extensive use of unrelated HCT for such patients may minimize the potential disadvantage of lacking a related donor.

Original languageEnglish
Pages (from-to)390-395
Number of pages6
JournalBone Marrow Transplantation
Issue number3
Publication statusPublished - 2013 Mar


  • AML
  • allogeneic hematopoietic cell transplantation
  • donor
  • first CR
  • related transplantation
  • unrelated transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation


Dive into the research topics of 'Effect of related donor availability on outcome of AML in the context of related and unrelated hematopoietic cell transplantation'. Together they form a unique fingerprint.

Cite this